



*Var det bunden?*

*Skal vi op?*

*Vi skulle ned igen*

*Er foråret på vej?*

*Var det den optur eller samles der kræfter?*

## Markedsobservationer september 2025

Onsdag d. 24. september 2025  
V/Steen Albrechtsen, Redaktør



**LIFE SCIENCE**  
Økonomisk Ugebrev

# DISCLAIMER

*Al investering er på eget ansvar*

og stol ikke på noget af hvad jeg siger 😊

# US, FDA og/eller Kaos

---




- *Ledelsesudskiftninger og fyringer (DOGE, m.m.)*
- *Vaccine-området i fokus (mæslinger, covid, m.v.)*
- *Autisme/tylenol nyeste påfund*
- *On-shoring af produktion*
- *Prisreformer (skal US priser ned eller ex-US op?)*

→ *Big pharma får afværget/udvandet det meste?*

# US, FDA og/eller Kaos

## FDA leadership that have quit or been dismissed



Source: FDA.gov, Canaccord Genuity research

# US, FDA og/eller Kaos

---

*"It has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies," Mr Marks wrote in a resignation letter....*

Peter Marks offered his letter of resignation to Health and Human Services (HHS) officials on Friday, after being given a choice between resigning or being fired.

"It has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies," Mr Marks wrote in a resignation letter, obtained by multiple US media outlets, referring to the agency's new leader Robert F Kennedy Jr.


Mr Marks was among the healthcare professionals who helped develop Covid-19 vaccines in the first Trump administration

<https://www.bbc.com/news/articles/cn8r87z8vl0o>


# NBI (12 mdr.)




# Næsten synkron XBI udvikling




# Nordisk Health Care ikke godt (Novo)




# Pæn blandt de lidt mindre aktier (samlet set!)



# Nordic-40 også nede



# Novo Nordisk



# Index oversight

<b>Symbol</b>	<b>Description</b>	<b>Last</b>	<b>1W +/-%</b>	<b>1M +/-%</b>	<b>3M +/-%</b>	<b>1Y +/-%</b>	<b>YTD +/-%</b>
HX20GI	OMX Helsinki Health Care GI	4.645,70	0,26%	-4,31%	1,02%	31,95%	40,79%
OHCG	OBX Health Care GR	323,98	-4,64%	-4,98%	13,81%	9,82%	21,38%
BIOTK	Next Biotech	-	0,51%	9,51%	44,01%	36,49%	15,46%
FN20GI	First North Health Care GI	1.100,99	-3,27%	-8,70%	2,98%	5,54%	11,88%
NBI	<b>NASDAQ Biotechnology</b>	4.805,87	1,37%	1,44%	14,99%	0,55%	<b>11,49%</b>
XBI	<b>SPDR S&amp;P Biotech ETF</b>	96,77	3,23%	6,43%	17,62%	-2,44%	<b>7,45%</b>
SX20GI	OMX Stockholm Health Care GI	4.501,92	-1,04%	-5,12%	2,99%	-6,18%	-0,96%
SX201030	OMX Stockholm Pharmaceuticals and Biotechnology GI	7.328,03	-0,13%	-4,23%	6,69%	-5,52%	-2,29%
N20RGI	<b>N Health Care EUR GI</b>	5.648,06	1,80%	0,78%	-7,67%	-38,78%	<b>-24,10%</b>
CX20GI	<b>OMX Copenhagen Health Care GI</b>	6.290,05	2,78%	2,38%	-10,54%	-45,28%	<b>-30,04%</b>
OMXN40	<b>OMX Nordic 40</b>	2.341,09	1,49%	0,25%	1,59%	-15,59%	<b>-6,21%</b>

# Norden (top 25)

Selskab	1Y +/-%	YTD +/-%	Markedsværdi, mia. Land
AstraZeneca	-10,28%	-2,21%	2.193.455 Sweden
Novo Nordisk B	-54,94%	-39,92%	1.271.468 DK
Novonosis (Novozymes) B	-19,31%	-6,01%	158.857 DK
Coloplast B	-35,18%	-27,02%	120.613 DK
Genmab	13,02%	22,71%	117.594 DK
SOBI	-13,54%	-12,67%	99.075 Sweden
SECTRA B	16,77%	13,79%	57.299 Sweden
Getinge B	-7,22%	16,77%	53.880 Sweden
Demant	-10,72%	-10,45%	50.584 DK
ALK-Abelló B	14,54%	29,73%	41.810 DK
Camurus	8,09%	20,51%	40.659 Sweden
H. Lundbeck B	0,04%	9,20%	35.942 DK
Zealand Pharma	-45,96%	-35,57%	32.899 DK
Ambu	-27,78%	-7,26%	22.663 DK
AddLife B	15,82%	35,47%	21.925 Sweden
BioArctic B	75,75%	43,16%	21.172 Sweden
BONESUPPORT HOLDING	-2,04%	-20,73%	20.192 Sweden
Medicover B	36,32%	36,46%	19.481 Sweden
Elekta B	-24,02%	-17,50%	18.595 Sweden
Bavarian Nordic*	-3,80%	21,68%	18.256 DK
GN Store Nord	-25,51%	-11,70%	17.823 DK
Vitrolife	-47,47%	-40,23%	17.405 Sweden
Embla Medical	8,14%	-6,74%	14.291 DK
ChemoMetec	52,92%	32,35%	11.198 DK
Ambea	44,94%	37,13%	11.135 Sweden

Simpel gns. -1,66% 3,24%

# DK top-13 (Genmab og AK er succeshistorierne)

## derudover ChemoMetec, Bavarian og Lundbeck

Selskab	1Y +/-%	YTD +/-%	Markedsværdi, mia.
Novo Nordisk B	-54,94%	-39,92%	1.271.468
Novonesis (Novozymes) B	-19,31%	-6,01%	158.857
Coloplast B	-35,18%	-27,02%	120.613
Genmab	13,02%	22,71%	117.594
Demant	-10,72%	-10,45%	50.584
ALK-Abelló B	14,54%	29,73%	41.810
H. Lundbeck B	0,04%	9,20%	35.942
Zealand Pharma	-45,96%	-35,57%	32.899
Ambu	-27,78%	-7,26%	22.663
Bavarian Nordic*	-3,80%	21,68%	18.256
GN Store Nord	-25,51%	-11,70%	17.823
Embla Medical	8,14%	-6,74%	14.291
ChemoMetec	52,92%	32,35%	11.198
<i>Simpel gns.</i>	-10,35%	-2,23%	

# Norden - nyhedsstrøm

---

## 2025

- Fedme-crash
- Makro / Told / Geopolitik
- FDA-kaos
- US-produktion / reformer
- Renter

## Fravær af store opkøb

- Forkølet Bavarian-bud
- Små overtagelser hist og pist
- Integrum?

## Partneraftaler mange

- Zealand
- Gubra
- BioArctic x 2
- Camurus
- Saniona x 2
- Cantargia
- Alligator?
- Ascelia?

## Norden i USA

- Y-mabs købstilbud
- Ascendis flot performance
- IO Biotech tæt på?

# Integrum provides update on OsteoCentric's public offer and provides correction of previous announced information



THU, SEP 18, 2025 02:45 CET

[Report this content](#)

Mölnådal, Sweden, September 18<sup>th</sup>, 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B). Reference is made to Integrum's press release published 17 September 2025 at 00:30 CEST, in which Integrum stated it would return to the market as new information becomes available. Today, Integrum can report the following.

## Correction regarding acceptance forms and VP account numbers

On the contrary to the press release on 17 September 2025 at 00:30 CEST, it has been established that the two acceptance forms submitted by Integrum's founder and largest shareholder, Dr. Rickard Bråneberg, to Avanza on 9 September 2025 contained incorrect information regarding VP account numbers, meaning that the acceptance form was not complete as previously stated, also meaning it was not possible to register the acceptances. It has also therefore been established that there was not technical issue that caused the missed acceptance.

The error arose because the VP account numbers stated corresponded to a company that previously held Rickard Bråneberg's shares in Integrum. An investigation shows that this former company was merged into Rickard Bråneberg's current holding company, Pericardium, in 2017. Through the merger, assets and liabilities, including the Integrum shares, were transferred to the new holding company. The former company ceased to exist as a result of the merger. Information about the relevant VP accounts has not been visible to Rickard Bråneberg via his deposit account at his bank.

In the Euroclear Sweden (VPC) system, one of the referenced VP accounts is blocked, with a small number of shares remaining on that account, and the other account has been closed. At some point after 2017, the shares that, following the merger, were owned by Pericardium were moved to a new VP account in that company's name.

Following the submission of the acceptance forms, representatives from Avanza and Rickard Bråneberg's contact person at his bank were in contact to enable Avanza, as receiving agent, to gather and block (Sw. *apportreservering*) Pericardium's shareholding in accordance with the acceptance form instructions.

On 12 September 2025, the contact person at Rickard Bråneberg's bank informed Avanza that the bank would investigate the matter further regarding the release of the shares from the VP accounts. Rickard Bråneberg was copied to that email from the contact person.

On 15 September 2025 at 13:42 CEST, the contact person informed Avanza that Rickard Bråneberg would need to contact Euroclear to investigate why the shares could not be transferred. This information was not communicated by the contact person to Rickard Bråneberg.

## Additional observations

# Integrum – 1 mia. SEK deal

---

## Additional observations

Following the 12 September 2025 correspondence, Rickard Brånemark did not receive any further contact regarding the fact that his shares could not be delivered to or blocked by Avanza.

The offeror did not contact Rickard Brånemark, Integrum or any of Integrum's advisors with a request that the shares must be moved to Avanza or to correct the VP account information. Instead, the offeror chose not to include Rickard Brånemark's shares in the acceptance tally, resulting in the acceptance condition not being met. It must be noted that the acceptance form expressly states that "an incomplete or incorrectly completed acceptance form may be disregarded".

Had the offeror wished to complete the offer, Rickard Brånemark could have been contacted by the offeror to correct the VP account numbers on the acceptance forms. The offeror could also have postponed the outcome announcement at 07:00 CEST on 16 September 2025 to resolve the issue, or acknowledged approximately 69 percent accepted and extended the offer to allow Rickard Brånemark to supplement his forms with the correct VP account numbers. Rickard Brånemark had, after all, signed an irrevocable undertaking to tender all of his A and B shares in Integrum.

## Board statement and next steps

The Board of Directors considers the situation deeply regrettable. In the Board's view, more could have been done to satisfy the acceptance condition. However, the offeror chose to close the offer and not to facilitate a correction of the acceptance forms by Rickard Brånemark. Questions as to the reasons for this should be addressed to the offeror.

Integrum has decided not to proceed with any further review of whether the acceptance condition was met by requesting a statement from the Swedish Securities Council (Sw. *Aktiemarknadsnämnden*), following discussions with our legal advisors.

As stated above and in Integrum's earlier communication, the Company will provide further updates to the market if and when new information becomes available.

# Integrum – 1 mia. SEK deal

---

## Additional observations

Following the 12 September 2025 correspondence, Rickard Brånemark did not receive any further contact regarding the fact that his shares could not be delivered to or blocked by Avanza.

The offeror did not contact Rickard Brånemark, Integrum or any of Integrum's advisors with a request that the shares must be moved to Avanza or to correct the VP account information. Instead, the offeror chose not to include Rickard Brånemark's shares in the acceptance tally, resulting in the acceptance condition not being met. It must be noted that the acceptance form expressly states that "an incomplete or incorrectly completed acceptance form may be disregarded".

Had the offeror wished to complete the offer, Rickard Brånemark could have been contacted by the offeror to correct the VP account numbers on the acceptance forms. The offeror could also have postponed the outcome announcement at 07:00 CEST on 16 September 2025 to resolve the issue, or acknowledged approximately 69 percent accepted and extended the offer to allow Rickard Brånemark to supplement his forms with the correct VP account numbers. Rickard Brånemark had, after all, signed an irrevocable undertaking to tender all of his A and B shares in Integrum.


## Board statement and next steps

The Board of Directors considers the situation deeply regrettable. In the Board's view, more could have been done to satisfy the acceptance condition. However, the offeror chose to close the offer and not to facilitate a correction of the acceptance forms by Rickard Brånemark. Questions as to the reasons for this should be addressed to the offeror.

Integrum has decided not to proceed with any further review of whether the acceptance condition was met by requesting a statement from the Swedish Securities Council (Sw. *Aktiemarknadsnämnden*), following discussions with our legal advisors.

As stated above and in Integrum's earlier communication, the Company will provide further updates to the market if and when new information becomes available.


# Integrum – år-til-dato



# Integrum – historisk



# Fedme 12 mdr (24sep2025)



# Fedme år-til-dato (aug25)

(kilde: [https://x.com/paras\\_biotech/status/1959665240024764543](https://x.com/paras_biotech/status/1959665240024764543))

Company	YTD performance	Obesity stage
Altimune	-51	Phase 2
Veru	-45	Phase 2
Novo Nordisk	-40	Commercial
Zealand Pharma	-40	Phase 3
Gubra	-39	Phase 1
Viking Therapeutics	-36	Phase 3
Aardvark Therapeutics	-35	Phase 1
Structure Therapeutics	-27	Phase 2
BioAge Labs	-22	Phase 1
Eli Lilly	-8	Commercial
Metsera	28	Phase 2
Skye Bioscience	25	Phase 2
Terns Pharmaceuticals	22	Phase 2

Note: YTD performance as of Aug. 21. Metsera and Aardvark Therapeutics went public in January and February, respectively.

Table: Endpoints News • Source: Yahoo Finance • Created with Datawrapper

# Fedme - observationer

---

## Fra jubeloptimisme til dommedagspessimisme

- Størrelsen af det fremtidige marked (volumen og pris)
- Markedsfordelingen
- Teknologier, virkningsmekanisme, administration, etc.

# Fedme - observationer

---

## Fra jubeloptimisme til dommedagspessimisme

- Størrelsen af det fremtidige marked (volumen og pris)
- Markedsfordelingen
- Teknologier, virkningsmekanisme, administration, etc.

**Størrelse:** *Fra 50-60 mia. USD til 150 mia. USD og lidt retur*

**Markedsfordeling:** *Novo Nordisk og Eli Lilly deler markedet til Novo bliver en lille spiller*


**Teknologier:** *Fra GLP1-injectibles til piller og kombinationer*

*Se også Morten Larsen indlæg fra 23. april 2025*

<https://konferencer.ugebrev.dk/event/investor-konference-den-23-april/>

# Fedme – seneste markedsestimat

*nature* via <https://x.com/DrSamuelBHume/status/1970597946296250740>



**Fig. 1 | Estimated major-market sales of obesity drugs.** The 2023, 2029 and 2033 sales forecast for the seven major markets: the United States; France; Germany; Italy; Spain; the United Kingdom; and Japan. Legacy drugs include: orlistat, Contrave/Mysimba, Qsymia, and noradrenergic anorectics (phentermine, mazindol, benzphetamine, phendimetrazine, and diethylpropion).

# Fedme – seneste markedsestimat

*nature* <https://www.nature.com/articles/d41573-025-00155-2>

*"Five new therapies are expected to launch by 2033: oral semaglutide and CagriSema (Novo Nordisk), orforglipron and retatrutide (Eli Lilly), and survodutide (Boehringer Ingelheim). Although GLP-1 mono-agonists will drive growth, multi-receptor agonists — tirzepatide, CagriSema, retatrutide, and survodutide — are forecasted to dominate, generating nearly \$44 billion (77%) of total projected 2033 sales."*

*"Wegovy led obesity sales in 2024, but its market share is expected to decline due to competition from more effective therapies. Entry of lower-cost generics in Japan and major markets in Europe in 2031 and in the US in 2032 will temper this downward trend. Tirzepatide is expected to become and remain the leading agent in both sales and patient share, based on strong efficacy and outcomes data in a broad range of obesity comorbidities."*

*"CagriSema, building on semaglutide's well-established profile, is poised to be perceived as an upgraded semaglutide and could see a robust uptake and sustained sales growth, supporting Novo Nordisk's position in the obesity market. Survodutide may see slower adoption owing to anticipated low GI tolerability and limited familiarity with glucagon analogues. However, if its MASH-focused programme succeeds, it could become an attractive option for patients with obesity and MASH. Even if initial uptake may be limited by its late entry, retatrutide is expected to be positioned as best-in-class for patients with severe obesity and multiple comorbidities, claiming a considerable share of the market."*

# Fedme – seneste markedsestimat

*nature* <https://www.nature.com/articles/d41573-025-00155-2>

---

*“Oral options will further expand access and use. Among the two late-stage oral GLP-1 RAs, orforglipron — a fasting-free small-molecule with efficacy comparable to semaglutide — is likely to lead. Conversely, the uptake of oral semaglutide will be held back by the fasting requirements characteristic of oral peptides, and competition from orforglipron.”*

*“Looking ahead, current and next-generation agents — featuring greater efficacy, novel mechanisms, and potential synergies — have the potential to broaden obesity drug treatment further and improve outcomes in this disease.”*

*“According to Clarivate Disease Landscape & Forecast, obesity drug sales in the seven major markets will rise from US\$5.5 billion in 2023 to \$57 billion in 2033 (compound annual growth rate, 26%, Fig. 1). Key drivers include highly effective drugs, increasing treatment rates, and broader access. Yet, high prices and the scale of the eligible population make universal treatment economically unfeasible under current models.”*

# Fedme – oversigt vægttab og discontinuation

<https://x.com/DrSamuelBHume/status/1969108020756877608>

<https://www.nejm.org/doi/full/10.1056/NEJMoa2500969> (NEJM - Oral Wegovy)


<https://www.nejm.org/doi/full/10.1056/NEJMoa2511774> (NEJM - Orforglipron)

## Anti-Obesity Medicines

Drug	Dose	Mode-of-action	Weight loss (%)	Discontinuation (%)	Timepoint	Dosing	Company	Stage
Retatrutide	12 mg	GIP/GLP-1/Glucagon RA	22.1	16.0	48 weeks	Weekly, subcut	Eli Lilly	Phase 3 (underway)
Retatrutide	8 mg	GIP/GLP-1/Glucagon RA	21.8	6.0	48 weeks	Weekly, subcut	Eli Lilly	Phase 3 (underway)
Tirzepatide	15 mg	GIP/GLP-1 RA	17.8	3.6	72 weeks	Weekly, subcut	Eli Lilly	Approved
CagriSema	2.4 mg Cagri, 2.4 mg Sema	Amylin RA + GLP-1 RA	17.3	2.4	68 weeks	Weekly, subcut	Novo Nordisk	Phase 3 (underway)
Tirzepatide	10 mg	GIP/GLP-1 RA	16.4	4.6	72 weeks	Weekly, subcut	Eli Lilly	Approved
Mazdutide	6 mg	GLP-1/Glucagon RA	13.7	0.0	48 weeks	Weekly, subcut	Innovent	Approved (China)
MariTide	420 mg (12 week dose escalation)	GLP-1 RA + GIPR antagonist	13.7	11.0	52 weeks	Monthly, subcut	Amgen	Phase 3 (underway)
Pemvidutide	2.4 mg	GLP-1/Glucagon RA	13.4	0.0	48 weeks	Weekly, subcut	Altimmune	Phase 3 (underway)
Ecnoglutide	2.4 mg	Biased GLP-1 RA	13.3	3.0	40 weeks	Weekly, subcut	Sciwind	Phase 3 (complete)
VK2735	15 mg	GLP-1/GIP RA	13.1	6.0	13 weeks	Weekly, subcut	Viking	Phase 3 (underway)
Semaglutide	50 mg	Oral GLP-1 RA	12.7	2.0	68 weeks	Daily, oral	Novo Nordisk	Phase 3 (complete)
Semaglutide	2.4 mg	GLP-1 RA	12.4	3.9	68 weeks	Weekly, subcut	Novo Nordisk	Approved
Survodutide	4.8 mg	GLP-1/Glucagon RA	12.1	20.7	46 weeks	Weekly, subcut	Boehringer Ingelheim/Zealand	Phase 3 (underway)
MariTide	420 mg (4 week dose escalation)	GLP-1 RA + GIPR antagonist	11.6	9.0	52 weeks	Monthly, subcut	Amgen	Phase 3 (underway)
Semaglutide	25 mg	Oral GLP-1 RA	11.4	0.7	64 weeks	Daily, oral	Novo Nordisk	Phase 3 (complete)
Orforglipron	36 mg	Oral non-peptide GLP-1 RA	9.1	7.6	72 weeks	Daily, oral	Eli Lilly	Phase 3 (complete)
Phentermine/Topiramate	15 mg/92 mg	Sympathomimetic + CA inhibitor	8.6	7.6	56 weeks	Daily, oral	Vivus	Approved
Liraglutide	3 mg	GLP-1 RA	5.4	5.5	56 weeks	Daily, subcut	Novo Nordisk	Approved
Naltrexone/Bupropion	32 mg/360 mg	Opioid antagonist + NDRI	5.2	12.0	56 weeks	Twice-daily, oral	Currax	Approved
Orlistat	120 mg	Pancreatic lipase inhibitor	2.4	3.8	52 weeks	Thrice-daily, oral	Roche/GSK	Approved

# Fedme – nyhedsstrøm 2025 *(feb2025)*

## Key 2025 Events



Source: TD Cowen, Company reports  
Timing is illustrative

# Modelporteføljen -5% YTD (10sep2025)

Dato	Navn	Vægt	Antal	Kurs 10sep)	Købskurs	Købssum DKK	+/- DKK	+/- %
01jul+30nov2016	Zealand Pharma	7,9%	200	422,90	114,67	22.969	61.527	267,9%
okt16+apr23+sep24	Immunovia	1,2%	29.750	0,62	6,21	134.593	-121.980	-90,6%
feb17+jan22+dec24	Cantargia	7,2%	42.499	2,66	3,42	102.856	-25.801	-25,1%
aug24+jan+mar2020	Elektro B	8,2%	2.800	46,14	83,34	160.006	-71.947	-45,0%
okt2020+jan2022	Lundbeck A	1,6%	500	34,30	35,29	17.671	-539	-3,0%
okt2020+jan2022	Lundbeck B	7,8%	2.000	41,80	35,29	70.686	12.831	18,2%
nov20+jan21+jun22	Xspray	4,7%	1.647	45,30	94,49	111.808	-60.953	-54,5%
jun21+jun23	Infant Bacterial TI	5,4%	1.200	71,50	87,61	76.419	-17.937	-23,5%
jan+nov22+feb23+sep	Ascelia	4,3%	17.500	3,86	2,54	29.785	16.199	54,4%
19jan2022	Camurus	6,9%	150	723,00	132,50	14.316	59.605	416,3%
apr22+feb23	Hansa Biopharmæ	3,0%	1.600	29,42	60,00	66.374	-34.288	-51,7%
12-feb-25	Alligator	3,1%	12.738	3,80	6,84	58.067	-25.074	-43,2%
26jan24+12mar25	Genmab	9,0%	55	1.769,00	1770,73	97.488	-290	-0,3%
14-apr-25	Ascelia TO 1-udn	4,0%	16.536	3,86	2,15	23.367	20.084	85,9%
04-sep-24	Prostatype Genor	0,2%	5.250	0,58	8,84	30.445	-28.369	-93,2%
04-jun-25	ProGen BTU	0,8%	21.000	0,58	1,00	14.324	-6.022	-42,0%
07-okt-24	Egetis Therapeuti	6,4%	20.000	5,01	4,40	57.786	10.512	18,2%
05-dec-24	Vicore Pharma	5,0%	7.000	11,30	7,70	34.973	18.943	54,2%
12-mar-25	Novo Nordisk	2,4%	75	351,15	508,00	38.138	-11.828	-31,0%
		89,0%						

Gevinst/tab på seneste solgte aktier			Antal	Salgskurs	Købskurs	Købssum	+/- DKK	+/-
12. maj 2025	Ascelia Pharma		10.000	3,85	2,54	17.020	9.288	54,6%
16. april 2025	Ascelia Pharma		10.000	3,05	2,54	17.020	3.395	19,9%
24. januar 2025	Alligator		91.071	0,06	0,63	36.518	-32.967	-90,3%
13. december 2024	Ascelia Pharma		14.608	3,50	2,54	24.863	8.159	32,8%
22. november 2024	Thor Medical (Nordic Nanovector)		2.096	3,900	31,580	50.935	-45.668	-89,7%
9. september 2024	Calliditas Th.		1.000	208,000	69,800	46.147	88.628	192,1%
19. august 2024	Camurus		150	695,000	132,500	14.316	53.587	374,3%

## Porteføljeresultat


Startkapital pr. 26. ma	500.000	Investerbar kapital	1.280.414	Porteføljen	Siden start	2025	Seneste 2 uger
+ realiseret gevinst	780.414	Investeret	1.162.070		115,0%	-4,9%	2,4%
+ urealiseret gevinst	-205.327	Kontant	118.344	OMX Nordic Health	131,9%	-25,7%	0,8%
= kapital d.d.	1.075.087	Investeringsgrad	90,8%	OMX Nordic 40 Inc	42,4%	-7,5%	0,5%




**LIFE SCIENCE**  
Økonomisk Ugebrev

# Modelporteføljen – afkast 2024 til nu

MODELPORTEFOLJE OG REFERENCEINDEKS AFKAST PRIMO 2024-NU



# Inflation/rente/risiko Kilde: Leerink



Source: Leerink Partners Research, Factset, CME Group FedWatch (Data as of December 19, 2023).

**LEERINK**  
PARTNERS

 **LIFE SCIENCE**  
Økonomisk Ugebev

# Husk optimismen...

UGENS GRAFIK 3: BIOTECH-LINGO FOR INVESTORER

Biotech Jargon	What It Really Means
“Encouraging preclinical package”	Works in mice, but humans are a total gamble
“Breakthrough potential”	We have one patient who responded
“Robust biomarker signal”	Clinical efficacy is unclear, but at least the lab assays look busy
“Differentiated mechanism of action”	Nobody else is developing this because the biology is iffy
“We’re in active partnering discussions”	Big Pharma already passed, we’re hoping someone smaller bites
“On track for Phase 2 initiation”	Still trying to find a CRO and finalize the protocol
“Strong cash runway”	12 months of cash, then another dilutive raise
“Focused pipeline strategy”	We killed everything except one asset to survive
“Unmet medical need”	No FDA-approved therapy exists... for good reason
“Upcoming catalyst-rich year”	One clinical readout, plus a lot of press releases
“Committed to patient centricity”	We have no data, but we do have a patient advisory board slide

Kilde: @BowTiedBiotech (<https://x.com/BowTiedBiotech/status/1962168753770074435>)

---

# Tak for i dag!

Økonomisk Ugebrev A/S

facebook

LinkedIn

Spørgsmål, abonnement, ris/ros eller kommentarer

[sa@ugebrev.dk](mailto:sa@ugebrev.dk)



**LIFE SCIENCE**

Økonomisk Ugebrev